Lonza to invest over £150 million on new molecule complex

pharmafile | April 23, 2021 | News story | Medical Communications Lonza 

Lonza have announced the construction of a new small molecule manufacturing complex at its Visp site in Switzerland, which will cost CHF 200 million (Swiss franc) to build.

The new complex will occupy an overall footprint of approximately 2000 m2 with six levels of manufacturing space, which will include a customer dedicated production line for antibody-drug conjugate payload molecules.

The complex will have several opportunities for future expansions supporting the small molecules technologies offering, which include drug substance, particle engineering technologies such as spray drying dispersion, and drug product.

Maurits Janssen, Strategic Business Development Small Molecules at Lonza, said: “Supply is critical for our global partner in the oncology field. With this investment, we are enabling the treatment of many cancer patients. Oncology continues to be the leading indication in biopharma and a key driver for highly potent ingredients such as antibody-drug conjugates.

“In addition, small molecule oncology therapies require specific technologies. These challenges were specifically taken into account when designing this manufacturing complex.”

The investment is supported by a long-term collaboration and capital contribution with a major biopharmaceutical partner and the complex has been designed to accommodate future small molecule expansions.

Gordon Bates, President and Head of Small Molecules at Lonza, said: “This collaboration is a great example of how we are supporting our customers with flexible business models. Our customers developing highly potent and increasingly complex medicines trust us to handle these toxic substances throughout their clinical and commercial lifecycle.

“The investment to realise this new manufacturing complex for small molecules creates a substantial footprint for accelerating future growth capacity across the range of our small molecule service offering.”

The site is expected to start its first operations in Q3 2023 and upon completion, the manufacturing complex will employ approximately 200 people.

Kat Jenkins

Related Content

Lonza to acquire Synaffix to strengthen ADC development

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has …


Moderna submits BLA with FDA for COVID vaccine

Moderna has initiated the rolling submission process with the FDA for a Biologics License Application …


Altimmune expands COVID-19 vaccine manufacturing deal with Lonza

Altimmune has expanded its previously-announced AdCOVID vaccine manufacturing collaboration with Lonza. Under the expanded agreement, …

Latest content